Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rhenovia Files Two Patent Applications for RHEpatch™

Published: Friday, March 22, 2013
Last Updated: Friday, March 22, 2013
Bookmark and Share
An electronic transdermal patch for controlled drug delivery.

Rhenovia Pharma has announced that it has filed two patent applications for RHEpatch™, Rhenovia’s electronic transdermal patch for people suffering from chronic diseases.

RHEpatch was originally designed to optimize the delivery of drugs to patients suffering from diseases of the nervous system. However, Rhenovia now expects it to have a considerable impact across the entire health sector.

Its principal aim is to control dosing, treatment time and duration, day and night, for up to seven drugs administered to each patient. Control is achieved through a built-in electronic system pre-programmed by the doctor.

RHEpatch thus provides better control over the delivery of several drugs prescribed as a polytherapy, especially for the elderly.

RHEpatch is also designed to deliver the combinations of compounds needed to treat complex nervous system diseases such as Alzheimer’s disease.

It will also automatically control the administration of drugs, thus reducing the risk of patients forgetting. This facilitates treatment of patients with reduced mobility and prevents confused patients from taking repeated doses of drugs.

RHEpatch has many advantages over existing transdermal patches, which have drug release systems that are mainly passive (the treatment begins when the patch is put on and ends when it is taken off).

RHEpatch also indicates the amount of product actually delivered and the amount remaining in the patch.

In addition, unlike other transdermal patches, Rhenovia’s technology allows closely-controlled administration of several drugs through the same vector.

“This unique drug delivery device is going to have a major impact on the way medicines are used in the coming years,” said Dr. Serge Bischoff, president and CEO of Rhenovia. “It will enable doctors and nurses to manage treatment regimes more efficiently and more safely, as well as significantly improving patients’ quality of life.”

“RHEpatch is going to improve the treatment of diseases as complex as Parkinson’s, Alzheimer’s and Huntington’s, which require polytherapies for optimal efficacy,” said Professor Michel Baudry, vice-president and scientific director of Rhenovia.

“Delivering several drugs to the right place at the right time and in the right dose is a major challenge,” said Michel Faupel, vice-president of Rhenovia and the designer of RHEpatch.

Faupel continued, “Up to now, no one has succeeded in doing that satisfactorily. Yet this kind of approach is essential for ensuring effective long-term treatment of chronic diseases. By combining multitherapies derived from Rhenovia’s simulators with the controlled administration afforded by this intelligent patch, Rhenovia is convinced it can meet that challenge.”

Rhenovia’s industrial partner, Portmann Instruments AG, also contributed to the design of RHEpatch.

Portmann Instruments, which is based in Biel-Benken, Switzerland, is specialized in high-precision instrumentation and manufactures customized components for RHEpatch.

With the completion of a three-year EU Eurostars partnership program between Rhenovia and Portmann Instruments, RHEpatch has now reached the pre-industrialization prototype stage.

Following technological and biological proof-of-concept studies, Rhenovia is now looking for pharmaceutical, industrial and financial partners to move on to the industrialization and out-licensing stage.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rhenovia Signs Two-year EUR 500,000 Partnership with AFM to Support its Simulation Technology for Diseases of the Nervous System
This strategic agreement will help accelerate development of Rhenovia’s unique technology and enable AFM to explore new avenues for the treatment of neurological diseases.
Thursday, December 09, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!